Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012386 · ClinicalTrials.gov registry record · Phase 1
CD36 in Nutrient Delivery and Its Dysfunction
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03012386 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 26 participants.
The verdict
NCT03012386, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.
Interventions
- DRUG Sildenafil Citrate in G allele carrier
- DRUG Sildenafil Citrate in non G allele carrier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-01 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03012386
The ClinicalTrials.gov registry entry for NCT03012386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sildenafil Citrate in G allele carrier is the first listed.
NCT03012386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03012386 about?
NCT03012386 is a clinical study titled "CD36 in Nutrient Delivery and Its Dysfunction". This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose...
What is the current status of trial NCT03012386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-01. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03012386?
The interventions under investigation include: Sildenafil Citrate in G allele carrier (DRUG), Sildenafil Citrate in non G allele carrier (DRUG).
Who is sponsoring clinical trial NCT03012386?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.